Pfizer beats Novo Nordisk for obesity biotech Metsera

Pfizer's offer of up to $86.25 in cash for each share of obesity drugs developer Metsera share tops the up to $86.20 Novo Nordisk was willing to pay. The financial consideration and the greater certainly of a deal close tipped the balance in Pfizer's favor, ending a bidding war for Metsera and its next-generation obesity medications.

Editor's Pick

Top Story Pfizer's Sweeter $10B Offer Beats Novo Nordisk in Bidding War for Obesity Biotech Metsera Pfizer's offer of up to $86.25 in cash for each share of obesity drugs developer Metsera share tops the up to $86.20 Novo Nordisk was willing to pay. The financial consideration and the greater certainly of a deal close tipped the balance in Pfizer's favor, ending a bidding war for Metsera and its next-generation obesity medications. Sponsored RCM Outsourcing: Balancing Human Expertise & Smart Technology Presented by Greenway Health Greenway Health blends smart technology with human expertise to elevate revenue cycle. Learn More.

Featured News

How Philips Uses Monitoring Tech to Help Close Care Access Gaps Philips is using its patient monitoring devices to help health systems deliver care more efficiently, especially in areas with specialist shortages. The company's connected devices enable continuous monitoring from home to hospital and back, which can reduce diagnostic delays and improve patient safety, said Nick Wilson, Philps' vice president of product. Amae Health Raises $25M to Improve Care for Severe Mental Illness Amae Health's Series B round was led by Altos Ventures and included participation from Quiet Capital, Bling Capital, Cedars-Sinai Ventures, Healthier Capital and 8VC. Stronger Data Governance and Reliability Standards Needed for Wearables to Power Tech-Enabled Care To shift wearables from wellness tools to useful drivers of disease management, the data they generate must be as trustworthy as it is plentiful. Clear frameworks that govern how information is gathered and used are needed, along with standards for the accuracy and reliability of devices More Than Meets the Eye: Using Eye Movements in Drug Development for Neurodegenerative Diseases We urgently need biomarkers that are sensitive, objective, and practical. Eye-movement measures are ready to fill this gap, not as distant innovations, but as tools available today.

Video   Video: How AI Is Tackling Administrative Burdens There is no question that EHRs have created major administrative burdens, noted Nikhil Buduma, CEO of Ambience Healthcare.  These systems are causing clinicians to spend most of their time on documentation and billing work instead of connecting with patients. Buduma said Ambience aims to solve this by integrating AI directly into EHR workflows to automate tasks before, during and after the visit. The goal is to remove non-clinical work so clinicians can focus on the patient in front of them and restore joy in practicing medicine.

Resources

Debunked Episode 21: The Drug Price Debate, AI in Healthcare Companies Face Consolidation But How Much? How many companies will be left standing once consolidation hits the AI in healthcare sector? Which pharma companies are working with the Trump administration to lower costs? View Now

MedCity News • PO Box 901 • New York, NY unsubscribe